Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Other hematologic neoplasm 9Sarcoma 5Lymphoid 5Thoracic 4Gynecologic 4Genitourinary 4Breast 4Other solid neoplasm 2Head & Neck 2Dermatologic 2Tumor-Agnostic 1Myeloid 1Endocrine 1

Conditions

Melanoma 2

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 194aldesleukin 148Interleukin-2 110fludarabine phosphate 106trametinib 85Temozolomide 83Dacarbazine 81fludarabine 80dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Magnetic Resonance Spectroscopy 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Specimen Handling 47Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Base Sequence × Dermatologic × Clear all
NCT01543113 2023-05-24

KitMel

Rennes University Hospital

Phase NA Completed
288 enrolled
Dermatologic

Melanoma

NCT04285749 2020-07-27

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡